Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_2
1
14%
Ph phase_1
6
86%

Phase Distribution

6

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
6(85.7%)
Phase 2Efficacy & side effects
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(3)
Terminated(4)

Detailed Status

Completed3
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (85.7%)
Phase 21 (14.3%)

Trials by Status

withdrawn114%
completed343%
terminated343%

Recent Activity

0 active trials
Showing 5 of 7
withdrawnphase_1

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

NCT01101581
completedphase_1

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

NCT00596804
completedphase_1

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

NCT00546793
terminatedphase_1

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

NCT00547066
terminatedphase_1

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

NCT01147393
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01101581Phase 1

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Withdrawn
NCT00596804Phase 1

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Completed
NCT00546793Phase 1

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Completed
NCT00547066Phase 1

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Terminated
NCT01147393Phase 1

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

Terminated
NCT00989586Phase 1

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Completed
NCT01390545Phase 2

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

Terminated

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7